Jim Simons
IBRX icon

Jim Simons’s ImmunityBio IBRX Stock Holding History

Jim Simons’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,231,770
Closed -$2.44M – 3445
2025
Q4 		$2.44M Buy
1,231,770
+215,571
+21% +$488K ﹤0.01% 1743
2025
Q3 		$2.5M Buy
+1,016,199
New +$2.62M ﹤0.01% 1926
2022
Q3 		– Sell
-401,681
Closed -$1.49M – 4190
2022
Q2 		$1.49M Buy
+401,681
New +$1.61M ﹤0.01% 2415
2022
Q1 		– Sell
-304,900
Closed -$1.85M – 4239
2021
Q4 		$1.85M Buy
304,900
+96,983
+47% +$729K ﹤0.01% 2201
2021
Q3 		$2.02M Buy
+207,917
New +$2.29M ﹤0.01% 2081
2020
Q3 		– Sell
-32,745
Closed -$402K – 3499
2020
Q2 		$402K Sell
32,745
-1,657,218
-98% -$9.36M ﹤0.01% 2936
2020
Q1 		$4.87M Buy
1,689,963
+55,038
+3% +$276K ﹤0.01% 1577
2019
Q4 		$6.2M Buy
1,634,925
+39,200
+2% +$66.7K ﹤0.01% 1730
2019
Q3 		$1.95M Buy
1,595,725
+83,400
+6% +$103K ﹤0.01% 2295
2019
Q2 		$1.54M Buy
1,512,325
+280,108
+23% +$323K ﹤0.01% 2478
2019
Q1 		$1.95M Buy
1,232,217
+155,000
+14% +$195K ﹤0.01% 2318
2018
Q4 		$1.25M Buy
1,077,217
+376,650
+54% +$862K ﹤0.01% 2469
2018
Q3 		$2.59M Buy
700,567
+180,167
+35% +$570K ﹤0.01% 2155
2018
Q2 		$1.59M Buy
520,400
+218,200
+72% +$808K ﹤0.01% 2390
2018
Q1 		$1.18M Buy
302,200
+69,300
+30% +$304K ﹤0.01% 2593
2017
Q4 		$1.05M Buy
232,900
+43,800
+23% +$207K ﹤0.01% 2645
2017
Q3 		$1.04M Buy
189,100
+99,700
+112% +$614K ﹤0.01% 2560
2017
Q2 		$679K Sell
89,400
-396,700
-82% -$1.71M ﹤0.01% 2684
2017
Q1 		$1.73M Buy
486,100
+461,600
+1,884% +$2.28M ﹤0.01% 2320
2016
Q4 		$140K Buy
+24,500
New +$163K ﹤0.01% 3057
2016
Q2 		– Sell
-16,700
Closed -$137K – 3408
2016
Q1 		$137K Buy
+16,700
New +$157K ﹤0.01% 3165

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Jim Simons's IBRX Position: Q1 2026 in Review

Jim Simons sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 1,231,770 shares — an estimated $2.44M sold.

Jim Simons first reported a position in IBRX in Q1 2016 and held it in 21 quarters. The position peaked at $6.2M in Q4 2019. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Jim Simons reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
  • Jim Simons sold 1,231,770 ImmunityBio shares in Q1 2026, an estimated $2.44M.
  • Jim Simons first reported a position in ImmunityBio in Q1 2016 and held it in 21 quarters.
  • Jim Simons's ImmunityBio position peaked at $6.2M in Q4 2019.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.